Support for the role of plaques in AD comes from post-mortem studies of brain specimens from participants in the Phase 2a active immunization trial that there was a significant reduction in amyloid pathology which correlated with an improvement in neurite abnormalities in the hippocampus and an amelioration of tau pathology [44]. This evidence concerns the gene MAPT and amyloidosis.